|
Jan 10
|
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 5
|
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ...
|
|
Jan 4
|
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
|
|
Dec 29
|
Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares
|
|
Dec 23
|
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...
|
|
Dec 18
|
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
|
|
Dec 3
|
12 Stocks Billionaire Steve Cohen Just Bought and Sold
|
|
Sep 15
|
Why Crinetics Pharmaceuticals Stock Soared This Week
|
|
Sep 13
|
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
|
|
Sep 11
|
Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63%
|
|
Sep 11
|
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Sep 11
|
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
|
|
Sep 11
|
Crinetics shares surge after "positive" hormonal disorder drug trial results
|
|
Sep 10
|
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
|
|
Aug 10
|
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|